Novartis Says Asciminib Showed Superior MMR Rate to Bosulif in Leukemia Trial
09 December 2020 - 3:00AM
Dow Jones News
By Michael Dabaie
Novartis AG said asciminib showed superior major molecular
response rate to Bosulif in a chronic myeloid leukemia trial.
The company said results from a Phase III study demonstrate that
at 24 weeks, asciminib nearly doubled the major molecular response
rate compared with Bosulif in patients resistant to, or intolerant
of, at least two prior tyrosine kinase inhibitor therapies.
The data were presented at a late-breaking abstracts session
during the 62nd American Society of Hematology Annual Meeting &
Exposition, Novartis said.
In the trial, 233 patients were randomized to receive asciminib
40 mg twice daily or Bosulif 500 mg once a day.
Novartis said the U.S. Food and Drug Administration granted Fast
Track designation for asciminib. The company said it plans
submission to U.S. and EU health authorities in the first half of
2021.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 08, 2020 10:45 ET (15:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024